Terence Stamp, best known for his role playing the villain General Zod in the blockbuster films Superman and Superman II, has ...

Novo Nordisk's (NVO) corrections amid AI market rotation might be an opportunity, due to GLP-1 market leadership & balanced ...

Mounjaro and other GLP-1 drugs may lower cancer risk in obese patients, according to a new study. Read more here.

Eli Lilly is one of the top growing stocks at the moment. Learn the reasons why this might be a stock to consider.

Eli Lilly raised the price of its GLP-1, Zepbound, from about $125 to $165 and plans an additional hike next month that would ...

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

GLP-1 drugs for diabetes and weight loss may influence patients’ cancer risk, usually lowering it but sometimes possibly increasing it, new findings suggest.

Eli Lilly's (LLY) recent earnings and GLP-1 trial results shook the biopharma market this week. Courtney Breen, Bernstein ...

Lilly's Kwikpen debut intensifies rivalry with Novo Nordisk's Wegovy in the world's most populous diabetes market ...

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...

Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...

Eli Lilly’s GLP-1 pill helped some participants lose up to 15% body weight. But is it as effective as the injection? Here's ...